Avondale Sees McKesson Corporation 'Stabilizing'

Loading...
Loading...
Avondale Partners lifted
McKesson CorporationMCK
's price target from $172 to $197. In its report published Tuesday, the analysts stated they believe the company is stabilizing, noting that it is still too early to make a conclusion because of macro factors.

"Operational excellence was the key theme across all of MCK's businesses, and we could sense a strong feeling of confidence exuded by management surrounding the growth opportunities for Distribution Solutions," wrote Avondale.

Related Link: Buy McKesson "Right Here, Right Now," Baird Says

The analysts kept their Market Perform rating unchanged and are waiting for concrete evidence concerning stabilized operations to reevaluate their estimates and price target. They stated several aspects concerning the company's growth beyond fiscal 2017 year, including:

  • The company will partially offset some of the larger customer losses (i.e., Rite Aid).
  • Reversion in generic prices should largely dissipate.
  • Higher specialty drug mix will drive DS operating profit dollar growth, albeit more in-line with revenue growth.

At time of writing, McKesson was trading down 0.47 percent on the day at $187.22.

date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorBiotechLong IdeasHealth CarePrice TargetAnalyst RatingsTrading IdeasGeneralAvondale Partners
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...